Curetis appoints Oliver Schacht as CEO
Curetis AG announced the appointment of Oliver Schacht (current CFO Epigenomics AG / CEO Epigenomics, Inc.) as CEO, effective 1st April 2011. The supervisory board of Curetis AG has appointed Oliver Schacht, Ph.D. (age 40), who has been serving as a supervisory board member since June 2010, to join the company full time as its CEO.
At Epigenomics, Oliver has proven his ability to build and grow a start-up biotech company into a commercially focused molecular diagnostics enterprise over the past 12 years. He brings a strong background in the global molecular diagnostics industry. His experience includes all aspects of strategic development and implementation, corporate finance and fundraising, product development from discovery of novel biomarkers and their clinical validation to the successful market launch of in-vitro diagnostic test kits.
Currently and until 31st March 2011, Oliver serves as CFO of Epigenomics AG (Berlin, Germany, 1999-today) and CEO of Epigenomics, Inc. (Seattle, USA, 2006-today). In these capacities he has been responsible for several private venture capital financings with top-tier VCs, an IPO on the Frankfurt Stock Exchange in 2004, a trans-Atlantic merger including successful postmerger integration, as well as two PIPE financings and two successful public rights offerings to shareholders in Europe and the USA in the past four years.
Over the past twelve years Oliver has raised over 150 million Euros in equity capital for Epigenomics and co-founded a number of other start-up companies. Oliver also led the corporate and business development teams at Epigenomics in signing strategic R&D collaborations as well as commercialization alliances in molecular diagnostics with partners such as Abbott, Roche, Qiagen, Quest Diagnostics, Sysmex, Philips, ARUP, Warnex as well as forging personalized medicine partnerships with pharmaceutical industry players Astra-Zeneca, J&J, Pfizer, Merck, Amgen and others. In his role as CEO of Epigenomics Inc., Oliver headed a team of up to 40 clinical R&D staff in addition to his commercial functions. Under his leadership Epigenomics Inc. ran a threeyear successful prospective clinical study enrolling almost 8,000 subjects at 32 clinical sites in the U.S. and Germany.
Oliver Schacht earned a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master’s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting from 1995 to 1999, he worked on projects in M&A, growth strategies and re-organization in pharma, biotech and other sectors.
Other news from the department people
